Drug Discovery

Sino and AstraZeneca sign licence agreement for TQC3721

AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.

Evogene and Tel Aviv University launch drug discovery initiative

Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research.

FDA grants rare paediatric designation to Vanda’s CMT2S therapy

The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).

Biocytogen and Whitehawk partner to develop ADCs

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Vertex signs agreement to acquire Crinetics for $10bn

Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

EC approves AbbVie’s Tepkinly combination for follicular lymphoma

The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R²) for adult patients with relapsed or refractory follicular lymphoma.

Novartis to acquire Myricx Bio in up to $1.5bn deal

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

Besins Healthcare boosts drug delivery portfolio with UniD deal

Besins Healthcare has expanded its pharmaceutical operations with the acquisition of Belgium-based UniD Manufacturing, which specialises in long-acting drug delivery technologies.

SK bioscience to lead Gates Foundation-funded ROTOR project

SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.